Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation and Depletion (2021 - 2024)

ARS Pharmaceuticals (SPRY) has disclosed Depreciation and Depletion for 4 consecutive years, with $29000.0 as the latest value for Q4 2024.

  • Quarterly Depreciation and Depletion rose 141.67% to $29000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $79000.0 through Dec 2024, up 8.22% year-over-year, with the annual reading at $79000.0 for FY2024, 8.22% up from the prior year.
  • Depreciation and Depletion hit $29000.0 in Q4 2024 for ARS Pharmaceuticals, up from $21000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $209000.0 in Q2 2021 to a low of -$37000.0 in Q2 2022.
  • Historically, Depreciation and Depletion has averaged $60562.5 across 4 years, with a median of $20500.0 in 2023.
  • Biggest five-year swings in Depreciation and Depletion: plummeted 117.7% in 2022 and later skyrocketed 200.0% in 2023.
  • Year by year, Depreciation and Depletion stood at $187000.0 in 2021, then tumbled by 92.51% to $14000.0 in 2022, then decreased by 14.29% to $12000.0 in 2023, then skyrocketed by 141.67% to $29000.0 in 2024.
  • Business Quant data shows Depreciation and Depletion for SPRY at $29000.0 in Q4 2024, $21000.0 in Q3 2024, and $18000.0 in Q2 2024.